D.A. Davidson & CO. Takes $87,000 Position in Lexicon Pharmaceuticals, Inc. (LXRX)

Share on StockTwits

D.A. Davidson & CO. purchased a new position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 13,080 shares of the biopharmaceutical company’s stock, valued at approximately $87,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Northern Trust Corp increased its holdings in shares of Lexicon Pharmaceuticals by 2.1% during the second quarter. Northern Trust Corp now owns 584,393 shares of the biopharmaceutical company’s stock valued at $7,013,000 after acquiring an additional 12,289 shares in the last quarter. Bank of Montreal Can increased its holdings in shares of Lexicon Pharmaceuticals by 8,364.1% during the third quarter. Bank of Montreal Can now owns 122,053 shares of the biopharmaceutical company’s stock valued at $1,302,000 after acquiring an additional 120,611 shares in the last quarter. First Trust Advisors LP bought a new position in shares of Lexicon Pharmaceuticals during the third quarter valued at $1,525,000. Candriam Luxembourg S.C.A. increased its holdings in shares of Lexicon Pharmaceuticals by 36.8% during the third quarter. Candriam Luxembourg S.C.A. now owns 509,000 shares of the biopharmaceutical company’s stock valued at $5,431,000 after acquiring an additional 137,000 shares in the last quarter. Finally, GSA Capital Partners LLP increased its holdings in shares of Lexicon Pharmaceuticals by 321.7% during the third quarter. GSA Capital Partners LLP now owns 74,586 shares of the biopharmaceutical company’s stock valued at $796,000 after acquiring an additional 56,900 shares in the last quarter.

Lexicon Pharmaceuticals stock opened at $5.12 on Thursday. Lexicon Pharmaceuticals, Inc. has a one year low of $4.26 and a one year high of $13.97. The firm has a market cap of $545.51 million, a P/E ratio of -4.03 and a beta of 0.63.

LXRX has been the subject of several analyst reports. Wedbush set a $36.00 price target on Lexicon Pharmaceuticals and gave the company an “outperform” rating in a report on Tuesday, January 22nd. Citigroup reduced their price target on Lexicon Pharmaceuticals from $27.00 to $26.00 and set a “buy” rating for the company in a report on Friday, November 2nd. BidaskClub raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, January 17th. ValuEngine raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 25th. Finally, Cowen reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Friday, November 2nd. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. Lexicon Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $17.90.

TRADEMARK VIOLATION WARNING: “D.A. Davidson & CO. Takes $87,000 Position in Lexicon Pharmaceuticals, Inc. (LXRX)” was first reported by Macon Daily and is the sole property of of Macon Daily. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://macondaily.com/2019/02/14/d-a-davidson-co-takes-87000-position-in-lexicon-pharmaceuticals-inc-lxrx.html.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Article: Analyst Ratings Trading

Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX).

Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply